<DOC>
	<DOC>NCT02577185</DOC>
	<brief_summary>The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.</brief_summary>
	<brief_title>An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Age 18 years or above A diagnosis of psoriasis vulgaris with lesions located on arms and/or legs and/or trunk Chronic stable psoriasis vulgaris diagnosed more than 6 months prior to screening. Women must use a reliable contraceptive during the trial. Pregnant or breast feeding women, or women planning to become pregnant. Skin infection at injection sites Use of biological therapies or small molecules (marketed or not marketed) with a possible effect on psoriasis vulgaris Use of systemic treatments with a potential effect on psoriasis vulgaris Exposure to phototherapy within 4 weeks for PUVA and 2 weeks for UVB prior to Randomisation Use of potent or very potent (WHO group IIIIV) corticosteroids for topical treatment of psoriasis within a 4 week period prior to randomisation Use of muscle relaxants History of dysphagia or aspiration Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>